Cargando…

A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3

Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor loss, providing a physiological mechanism for tumor suppression in premalignant cells. The link between senescence and tumor suppression supports the hypothesis that a loss-of-functi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lahtela, Jenni, Corson, Laura B., Hemmes, Annabrita, Brauer, Matthew J., Koopal, Sonja, Lee, James, Hunsaker, Thomas L., Jackson, Peter K., Verschuren, Emmy W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594263/
https://www.ncbi.nlm.nih.gov/pubmed/23324396
http://dx.doi.org/10.4161/cc.23515
_version_ 1782262315189534720
author Lahtela, Jenni
Corson, Laura B.
Hemmes, Annabrita
Brauer, Matthew J.
Koopal, Sonja
Lee, James
Hunsaker, Thomas L.
Jackson, Peter K.
Verschuren, Emmy W.
author_facet Lahtela, Jenni
Corson, Laura B.
Hemmes, Annabrita
Brauer, Matthew J.
Koopal, Sonja
Lee, James
Hunsaker, Thomas L.
Jackson, Peter K.
Verschuren, Emmy W.
author_sort Lahtela, Jenni
collection PubMed
description Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor loss, providing a physiological mechanism for tumor suppression in premalignant cells. The link between senescence and tumor suppression supports the hypothesis that a loss-of-function screen measuring bona fide senescence marker activation should identify candidate tumor suppressors. Using a high-content siRNA screening assay for cell morphology and proliferation measures, we identify 12 senescence-regulating kinases and determine their senescence marker signatures, including elevation of senescence-associated β-galactosidase, DNA damage and p53 or p16(INK4a) expression. Consistent with our hypothesis, SNP array CGH data supports loss of gene copy number of five senescence-suppressing genes across multiple tumor samples. One such candidate is the EPHA3 receptor tyrosine kinase, a gene commonly mutated in human cancer. We demonstrate that selected intracellular EPHA3 tumor-associated point mutations decrease receptor expression level and/or receptor tyrosine kinase (RTK) activity. Our study therefore describes a new strategy to mine for novel candidate tumor suppressors and provides compelling evidence that EPHA3 mutations may promote tumorigenesis only when key senescence-inducing pathways have been inactivated.
format Online
Article
Text
id pubmed-3594263
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35942632013-03-22 A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3 Lahtela, Jenni Corson, Laura B. Hemmes, Annabrita Brauer, Matthew J. Koopal, Sonja Lee, James Hunsaker, Thomas L. Jackson, Peter K. Verschuren, Emmy W. Cell Cycle Report Activation of a cellular senescence program is a common response to prolonged oncogene activation or tumor suppressor loss, providing a physiological mechanism for tumor suppression in premalignant cells. The link between senescence and tumor suppression supports the hypothesis that a loss-of-function screen measuring bona fide senescence marker activation should identify candidate tumor suppressors. Using a high-content siRNA screening assay for cell morphology and proliferation measures, we identify 12 senescence-regulating kinases and determine their senescence marker signatures, including elevation of senescence-associated β-galactosidase, DNA damage and p53 or p16(INK4a) expression. Consistent with our hypothesis, SNP array CGH data supports loss of gene copy number of five senescence-suppressing genes across multiple tumor samples. One such candidate is the EPHA3 receptor tyrosine kinase, a gene commonly mutated in human cancer. We demonstrate that selected intracellular EPHA3 tumor-associated point mutations decrease receptor expression level and/or receptor tyrosine kinase (RTK) activity. Our study therefore describes a new strategy to mine for novel candidate tumor suppressors and provides compelling evidence that EPHA3 mutations may promote tumorigenesis only when key senescence-inducing pathways have been inactivated. Landes Bioscience 2013-02-15 /pmc/articles/PMC3594263/ /pubmed/23324396 http://dx.doi.org/10.4161/cc.23515 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Report
Lahtela, Jenni
Corson, Laura B.
Hemmes, Annabrita
Brauer, Matthew J.
Koopal, Sonja
Lee, James
Hunsaker, Thomas L.
Jackson, Peter K.
Verschuren, Emmy W.
A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
title A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
title_full A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
title_fullStr A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
title_full_unstemmed A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
title_short A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
title_sort high-content cellular senescence screen identifies candidate tumor suppressors, including epha3
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594263/
https://www.ncbi.nlm.nih.gov/pubmed/23324396
http://dx.doi.org/10.4161/cc.23515
work_keys_str_mv AT lahtelajenni ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT corsonlaurab ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT hemmesannabrita ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT brauermatthewj ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT koopalsonja ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT leejames ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT hunsakerthomasl ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT jacksonpeterk ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT verschurenemmyw ahighcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT lahtelajenni highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT corsonlaurab highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT hemmesannabrita highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT brauermatthewj highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT koopalsonja highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT leejames highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT hunsakerthomasl highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT jacksonpeterk highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3
AT verschurenemmyw highcontentcellularsenescencescreenidentifiescandidatetumorsuppressorsincludingepha3